DK1248600T3 - Forbedrede farmaceutiske formuleringer - Google Patents

Forbedrede farmaceutiske formuleringer

Info

Publication number: DK1248600T3
Authority: DK; Denmark
Prior art keywords: improved pharmaceutical; pharmaceutical formulations; improved; mixtures; pharmaceutically acceptable
Prior art date: 2000-01-19

Application number

DK00982360T

Other languages

English (en)

Inventor

Soumojeet Ghosh

Laman Alani

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-19

Filing date

2000-12-01

Publication date

2008-09-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23936923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1248600(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-12-01 Application filed by Abbott Lab filed Critical Abbott Lab

2008-09-08 Application granted granted Critical

2008-09-08 Publication of DK1248600T3 publication Critical patent/DK1248600T3/da

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
108010010369 HIV Protease Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
150000004668 long chain fatty acids Chemical class 0.000 abstract 1
150000004667 medium chain fatty acids Chemical class 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)

DK00982360T 2000-01-19 2000-12-01 Forbedrede farmaceutiske formuleringer DK1248600T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48773900A	2000-01-19	2000-01-19
PCT/US2000/032771 WO2001052821A1 (en)	2000-01-19	2000-12-01	Improved pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
DK1248600T3 true DK1248600T3 (da)	2008-09-08

Family

ID=23936923

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK10177365.3T DK2269591T3 (da)	2000-01-19	2000-12-01	Forbedrede farmaceutiske formuleringer
DK07121429.0T DK1917958T3 (da)	2000-01-19	2000-12-01	Forbedrede farmaceutiske formuleringer af HIV proteaseinhibitorer
DK00982360T DK1248600T3 (da)	2000-01-19	2000-12-01	Forbedrede farmaceutiske formuleringer

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK10177365.3T DK2269591T3 (da)	2000-01-19	2000-12-01	Forbedrede farmaceutiske formuleringer
DK07121429.0T DK1917958T3 (da)	2000-01-19	2000-12-01	Forbedrede farmaceutiske formuleringer af HIV proteaseinhibitorer

Country Status (25)

Country	Link
EP (3)	EP1917958B1 (da)
JP (1)	JP4769400B2 (da)
KR (1)	KR100861885B1 (da)
CN (1)	CN100536833C (da)
AT (1)	ATE395049T1 (da)
AU (2)	AU1940501A (da)
BG (1)	BG66112B1 (da)
BR (1)	BR0011864A (da)
CA (1)	CA2395987C (da)
CY (3)	CY1108197T1 (da)
CZ (1)	CZ304118B6 (da)
DE (1)	DE60038899D1 (da)
DK (3)	DK2269591T3 (da)
ES (3)	ES2676151T3 (da)
HU (1)	HU229778B1 (da)
IL (2)	IL150265A0 (da)
MX (1)	MXPA02007097A (da)
NO (1)	NO331400B1 (da)
NZ (1)	NZ519724A (da)
PT (3)	PT2269591T (da)
SI (3)	SI1248600T1 (da)
SK (1)	SK287143B6 (da)
TR (1)	TR201809435T4 (da)
WO (1)	WO2001052821A1 (da)
ZA (1)	ZA200205109B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2359945C (en)	1999-11-12	2011-04-26	Abbott Laboratories	Inhibitors of crystallization in a solid dispersion
US7364752B1 (en)	1999-11-12	2008-04-29	Abbott Laboratories	Solid dispersion pharamaceutical formulations
US8025899B2 (en)	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
GB0615211D0 (en) *	2006-07-31	2006-09-06	Ge Healthcare Uk Ltd	Asymmetric flouro-substituted polymethine dyes
WO2009019661A1 (en) *	2007-08-07	2009-02-12	Ranbaxy Laboratories Limited	Process for preparation of amorphous lopinavir
WO2012164575A2 (en)	2011-05-27	2012-12-06	Hetero Research Foundation	Amorphous ritonavir co-precipitated
GB201808563D0 (en)	2018-05-24	2018-07-11	Univ Manchester	Treatments
GB201808564D0 (en)	2018-05-24	2018-07-11	Douglas Pharmaceuticals Ltd	Treatments
GB201907305D0 (en)	2019-05-23	2019-07-10	Douglas Pharmaceuticals Ltd	Treatment of conditions

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US594836A (en) *		1897-11-30		Corner-brace
US5354866A (en)	1989-05-23	1994-10-11	Abbott Laboratories	Retroviral protease inhibiting compounds
US5552558A (en)	1989-05-23	1996-09-03	Abbott Laboratories	Retroviral protease inhibiting compounds
GB8927913D0 (en)	1989-12-11	1990-02-14	Hoffmann La Roche	Amino acid derivatives
EP0813868B1 (en)	1990-11-19	2005-06-01	Monsanto Company	Retroviral protease inhibitors
CA2056911C (en)	1990-12-11	1998-09-22	Yuuichi Nagano	Hiv protease inhibitors
EP0532466A3 (en)	1991-09-12	1993-06-16	Ciba-Geigy Ag	Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
BR9206623A (pt)	1991-10-11	1995-05-02	Du Pont Merck Pharma	Uréias cíclicas e análogas úteis como inibidoras da protease retroviral
US5413999A (en)	1991-11-08	1995-05-09	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
ATE163926T1 (de)	1991-11-08	1998-03-15	Merck & Co Inc	Hiv-protease-inhibitoren verwendbar in der aids- behandlung
EP0560268B1 (en)	1992-03-13	1995-01-04	Bio-Mega/Boehringer Ingelheim Research Inc.	Substituted pipecolinic acid derivatives as HIV protease inhibitors
WO1993023368A1 (en)	1992-05-20	1993-11-25	G.D. Searle & Co.	Urea-containing hydroxyethylamine compounds as retroviral protease inhibitors
US5559256A (en)	1992-07-20	1996-09-24	E. R. Squibb & Sons, Inc.	Aminediol protease inhibitors
IS2334B (is)	1992-09-08	2008-02-15	Vertex Pharmaceuticals Inc., (A Massachusetts Corporation)	Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en)	1993-10-07	1996-01-16	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors
EP1302468B1 (en)	1992-12-29	2008-12-17	Abbott Laboratories	Processes and intermediates for manufacturing retroviral protease inhibiting compounds
AU7518694A (en)	1993-08-20	1995-03-21	G.D. Searle & Co.	Retroviral protease inhibitors and combinations thereof
IL110752A (en) *	1993-09-13	2000-07-26	Abbott Lab	Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
GB9319129D0 (en) *	1993-09-15	1993-11-03	Dowelanco Ltd	Storage and dilution of stable aqueous dispersions
US5559158A (en)	1993-10-01	1996-09-24	Abbott Laboratories	Pharmaceutical composition
US5491253A (en)	1993-10-22	1996-02-13	Abbott Laboratories	Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) *	1994-01-28	2000-07-26	Abbott Lab	Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
IL129871A (en)	1994-05-06	2003-11-23	Pharmacia & Upjohn Inc	Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5567823A (en)	1995-06-06	1996-10-22	Abbott Laboratories	Process for the preparation of an HIV protease inhibiting compound
US6037157A (en)	1995-06-29	2000-03-14	Abbott Laboratories	Method for improving pharmacokinetics
US5914332A (en)	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
EP1295874A3 (en) *	1995-12-13	2003-04-02	Abbott Laboratories	Retroviral protease inhibiting compounds
US6160122A (en)	1996-06-28	2000-12-12	Abbott Laboratories	Process for the preparation of a disubstituted thiazole
ZA9710071B (en)	1996-11-21	1998-05-25	Abbott Lab	Pharmaceutical composition.
ATE332132T1 (de) *	1999-06-04	2006-07-15	Abbott Lab	Verbesserte arzneizubereitungen enthaltend ritonavir

2000
- 2000-12-01 DK DK10177365.3T patent/DK2269591T3/da active
- 2000-12-01 KR KR1020027009316A patent/KR100861885B1/ko not_active Ceased
- 2000-12-01 EP EP07121429A patent/EP1917958B1/en not_active Revoked
- 2000-12-01 NZ NZ519724A patent/NZ519724A/en not_active IP Right Cessation
- 2000-12-01 WO PCT/US2000/032771 patent/WO2001052821A1/en not_active Ceased
- 2000-12-01 AU AU19405/01A patent/AU1940501A/en not_active Abandoned
- 2000-12-01 CN CNB008184798A patent/CN100536833C/zh not_active Expired - Lifetime
- 2000-12-01 ES ES10177365.3T patent/ES2676151T3/es not_active Expired - Lifetime
- 2000-12-01 EP EP10177365.3A patent/EP2269591B1/en not_active Revoked
- 2000-12-01 SI SI200030994T patent/SI1248600T1/sl unknown
- 2000-12-01 AT AT00982360T patent/ATE395049T1/de active
- 2000-12-01 CZ CZ20022663A patent/CZ304118B6/cs not_active IP Right Cessation
- 2000-12-01 TR TR2018/09435T patent/TR201809435T4/tr unknown
- 2000-12-01 CA CA002395987A patent/CA2395987C/en not_active Expired - Lifetime
- 2000-12-01 ES ES07121429T patent/ES2387579T3/es not_active Expired - Lifetime
- 2000-12-01 HU HU0302070A patent/HU229778B1/hu not_active IP Right Cessation
- 2000-12-01 EP EP00982360A patent/EP1248600B1/en not_active Revoked
- 2000-12-01 ES ES00982360T patent/ES2304990T3/es not_active Expired - Lifetime
- 2000-12-01 MX MXPA02007097A patent/MXPA02007097A/es active IP Right Grant
- 2000-12-01 DK DK07121429.0T patent/DK1917958T3/da active
- 2000-12-01 JP JP2001552869A patent/JP4769400B2/ja not_active Expired - Lifetime
- 2000-12-01 DE DE60038899T patent/DE60038899D1/de not_active Expired - Lifetime
- 2000-12-01 DK DK00982360T patent/DK1248600T3/da active
- 2000-12-01 SK SK1110-2002A patent/SK287143B6/sk not_active IP Right Cessation
- 2000-12-01 PT PT101773653T patent/PT2269591T/pt unknown
- 2000-12-01 PT PT07121429T patent/PT1917958E/pt unknown
- 2000-12-01 PT PT00982360T patent/PT1248600E/pt unknown
- 2000-12-01 SI SI200031095T patent/SI2269591T1/en unknown
- 2000-12-01 SI SI200031073T patent/SI1917958T1/sl unknown
- 2000-12-01 IL IL15026500A patent/IL150265A0/xx unknown
- 2000-12-01 BR BR0011864-8A patent/BR0011864A/pt not_active Application Discontinuation
2002
- 2002-06-17 IL IL150265A patent/IL150265A/en active IP Right Grant
- 2002-06-25 ZA ZA200205109A patent/ZA200205109B/xx unknown
- 2002-07-18 NO NO20023455A patent/NO331400B1/no not_active Application Discontinuation
- 2002-08-02 BG BG106976A patent/BG66112B1/bg unknown
2006
- 2006-11-07 AU AU2006235895A patent/AU2006235895B2/en not_active Revoked
2008
- 2008-07-16 CY CY20081100740T patent/CY1108197T1/el unknown
2012
- 2012-08-07 CY CY20121100711T patent/CY1112995T1/el unknown
2018
- 2018-07-03 CY CY20181100697T patent/CY1120408T1/el unknown

Also Published As

Publication number	Publication date
MXPA02007097A (es)	2003-01-28
KR20020082210A (ko)	2002-10-30
EP2269591B1 (en)	2018-04-04
JP4769400B2 (ja)	2011-09-07
BG66112B1 (bg)	2011-05-31
CA2395987A1 (en)	2001-07-26
DK1917958T3 (da)	2012-09-24
ATE395049T1 (de)	2008-05-15
CA2395987C (en)	2009-12-22
EP1248600B1 (en)	2008-05-14
SI2269591T1 (en)	2018-08-31
IL150265A (en)	2015-02-26
JP2003533435A (ja)	2003-11-11
PL361396A1 (en)	2004-10-04
AU2006235895A1 (en)	2006-11-30
AU2006235895B2 (en)	2009-08-13
CZ304118B6 (cs)	2013-11-06
BG106976A (bg)	2003-05-30
EP1917958A3 (en)	2008-08-27
HK1120213A1 (en)	2009-03-27
CZ20022663A3 (cs)	2002-11-13
HU229778B1 (hu)	2014-07-28
SK287143B6 (sk)	2010-01-07
ES2304990T3 (es)	2008-11-01
CY1108197T1 (el)	2014-02-12
ZA200205109B (en)	2003-10-31
NO20023455D0 (no)	2002-07-18
SK11102002A3 (sk)	2002-12-03
HUP0302070A3 (en)	2007-02-28
NO20023455L (no)	2002-09-18
CN1424907A (zh)	2003-06-18
NZ519724A (en)	2004-07-30
TR201809435T4 (tr)	2018-07-23
EP2269591A3 (en)	2011-07-27
ES2387579T3 (es)	2012-09-26
WO2001052821A1 (en)	2001-07-26
KR100861885B1 (ko)	2008-10-09
NO331400B1 (no)	2011-12-19
BR0011864A (pt)	2004-07-20
DK2269591T3 (da)	2018-07-16
ES2676151T3 (es)	2018-07-17
PT2269591T (pt)	2018-07-09
EP1917958A2 (en)	2008-05-07
CN100536833C (zh)	2009-09-09
EP1917958B1 (en)	2012-06-13
SI1917958T1 (sl)	2012-10-30
DE60038899D1 (de)	2008-06-26
SI1248600T1 (sl)	2008-08-31
PT1248600E (pt)	2008-08-25
AU1940501A (en)	2001-07-31
HUP0302070A2 (hu)	2003-09-29
CY1112995T1 (el)	2016-04-13
EP1248600A1 (en)	2002-10-16
PT1917958E (pt)	2012-08-16
EP2269591A2 (en)	2011-01-05
CY1120408T1 (el)	2019-07-10
IL150265A0 (en)	2002-12-01

Publication	Publication Date	Title
CY1112995T1 (el)	2016-04-13	Βελτιωμενες φαρμακοτεχνικες μορφες αναστολεων πρωτεασης ηιv
CY1109135T1 (el)	2014-07-02	Φαρμακευτικο διαλυμα το οποιο περιλαμβανει ριτοναβιρη, εναν διαλυτη (μακριας αλυσιδας λιπαρο οξυ) και νερο
FI20001750A0 (fi)	2000-08-04	Farmaseuttisia koostumuksia
ITMI20010748A0 (it)	2001-04-06	Composizioni farmaceutiche
MA26937A1 (fr)	2004-12-20	Nouvelle composition pharmaceutique.
NO20024891D0 (no)	2002-10-10	Farmasöytiske sammensetninger
BR9911160A (pt)	2001-04-03	Ciclosporinas
DE60105283D1 (de)	2004-10-07	Zusammensetzungen die molekulares iod enthalten
NO20032613D0 (no)	2003-06-10	Farmasöytisk sammensetning som har en forbedret vannopplöselighet
RU2001126719A (ru)	2004-02-20	Дигетерозамещенные ингибиторы металлопротеазы
EP1152051A3 (de)	2001-11-28	Wässrige Reinigungsmittel
PL350075A1 (en)	2002-11-04	Taxane formulations having improved solubility
NO20031909L (no)	2003-05-22	Selvemulgerende, orale doseringsformuleringer av pyranon protease-inhibitorer
IL145635A0 (en)	2002-06-30	Taxane formulations having improved solubility
IT1318962B1 (it)	2003-09-19	Procedimento per l'invio di messaggi pubblicitari direttamente adutenti.
SE0001916D0 (sv)	2000-05-23	Novel formulation
ITVA20000023A0 (it)	2000-07-19	Composizioni di pvc stabili al calore.
MA26966A1 (fr)	2004-12-20	Nouveaux composes utilisables en tant qu'inhibiteurs de protease hiv
IT1318654B1 (it)	2003-08-27	Composizioni farmaceutiche comprendenti agenti antiinfiammatori e lorousi.
IT1320768B1 (it)	2003-12-10	Composizioni farmaceutiche ad elevata attivita' antiossidante verso iradicali liberi.
IL136321A0 (en)	2001-05-20	Pharmaceutical compositions comprising cannabidiol derivatives